The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.
Public ClinicalTrials.gov record NCT04408937. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Investigator and Subject Blinded, Multicenter, Parallel-arm Study to Determine the Safety and Tolerability of Tropifexor.
Study identification
- NCT ID
- NCT04408937
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 89 participants
Conditions and interventions
Conditions
Interventions
- triopifexor Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 28, 2020
- Primary completion
- Nov 3, 2020
- Completion
- Nov 3, 2020
- Last update posted
- Feb 8, 2022
2020
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Madison | Alabama | 35758 | — |
| Novartis Investigative Site | Coronado | California | 92118 | — |
| Novartis Investigative Site | Miami | Florida | 33014-3616 | — |
| Novartis Investigative Site | Pensacola | Florida | 32503 | — |
| Novartis Investigative Site | South Bend | Indiana | 46635 | — |
| Novartis Investigative Site | Morehead City | North Carolina | 28557 | — |
| Novartis Investigative Site | Hermitage | Tennessee | 37076 | — |
| Novartis Investigative Site | Knoxville | Tennessee | 37920 | — |
| Novartis Investigative Site | Dallas | Texas | 75208-2312 | — |
| Novartis Investigative Site | San Antonio | Texas | 78215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04408937, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 8, 2022 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04408937 live on ClinicalTrials.gov.